Katyna Borroto–Esoda

6.2k total citations · 3 hit papers
91 papers, 4.2k citations indexed

About

Katyna Borroto–Esoda is a scholar working on Epidemiology, Infectious Diseases and Hepatology. According to data from OpenAlex, Katyna Borroto–Esoda has authored 91 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Epidemiology, 58 papers in Infectious Diseases and 33 papers in Hepatology. Recurrent topics in Katyna Borroto–Esoda's work include Hepatitis C virus research (33 papers), Hepatitis B Virus Studies (30 papers) and HIV/AIDS drug development and treatment (29 papers). Katyna Borroto–Esoda is often cited by papers focused on Hepatitis C virus research (33 papers), Hepatitis B Virus Studies (30 papers) and HIV/AIDS drug development and treatment (29 papers). Katyna Borroto–Esoda collaborates with scholars based in United States, France and Germany. Katyna Borroto–Esoda's co-authors include Patrick Marcellin, Michael D. Miller, Sarah Arterburn, David Angulo, Seng Gee Lim, Ting‐Tsung Chang, Steven L. Chuck, Stephanos J. Hadziyannis, Carol Brosgart and Florence Myrick and has published in prestigious journals such as Bioinformatics, Gastroenterology and Hepatology.

In The Last Decade

Katyna Borroto–Esoda

91 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years

2006 703 citations Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos et al. Gastroenterology profile →
The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation

2017 316 citations Emily L. Larkin, Christopher Hager et al. Antimicrobial Agents and Chemotherapy profile →
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

2021 230 citations William A. Fischer, Joseph J. Eron et al. Science Translational Medicine profile →

Peers

Katyna Borroto–Esoda

EPIDE

HEPAT

VIROL

Sandra De Meyer United States

A. Scott Muerhoff United States

Bruce Polsky United States

Judith M. Gottwein Denmark

Leen Vijgen Belgium

Douglas L. Mayers United States

Flor H. Pujol Venezuela

Margaret Tisdale United Kingdom

Rodolfo Campos Argentina

Robert D. Sitrin United States

Sandra De Meyer United States

Katyna Borroto–Esoda

1.3k ×0.4

EPIDE

1.9k ×0.9

1.2k ×0.6

HEPAT

1.1k ×2.0

VIROL

356 ×1.0

Citations per year, relative to Katyna Borroto–Esoda Katyna Borroto–Esoda (= 1×) peers Sandra De Meyer

Countries citing papers authored by Katyna Borroto–Esoda

Since Specialization

Citations

This map shows the geographic impact of Katyna Borroto–Esoda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katyna Borroto–Esoda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katyna Borroto–Esoda more than expected).

Fields of papers citing papers by Katyna Borroto–Esoda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katyna Borroto–Esoda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katyna Borroto–Esoda. The network helps show where Katyna Borroto–Esoda may publish in the future.

Co-authorship network of co-authors of Katyna Borroto–Esoda

This figure shows the co-authorship network connecting the top 25 collaborators of Katyna Borroto–Esoda. A scholar is included among the top collaborators of Katyna Borroto–Esoda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katyna Borroto–Esoda. Katyna Borroto–Esoda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huang, David B., et al.. (2021). Efficacy of Antistaphylococcal Lysin LSVT-1701 in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 65(8). e0050821–e0050821. 5 indexed citations

Fischer, William A., Joseph J. Eron, Wayne Holman, et al.. (2021). A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Science Translational Medicine. 14(628). eabl7430–eabl7430. 230 indexed citations breakdown →

Huang, David B., et al.. (2021). Anti-staphylococcal lysin, LSVT-1701, activity: In vitro susceptibility of Staphylococcus aureus and coagulase-negative staphylococci (CoNS) clinical isolates from around the world collected from 2002 to 2019. Diagnostic Microbiology and Infectious Disease. 101(3). 115471–115471. 4 indexed citations

Gamal, Ahmed, Sherman Chu, Thomas S. McCormick, et al.. (2021). Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata. Frontiers in Cellular and Infection Microbiology. 11. 642358–642358. 40 indexed citations

Larkin, Emily L., Christopher Hager, Jyotsna Chandra, et al.. (2017). The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Antimicrobial Agents and Chemotherapy. 61(5). 316 indexed citations breakdown →

Daito, Takuji, Koichi Watashi, Ann E. Sluder, et al.. (2014). Cyclophilin Inhibitors Reduce Phosphorylation of RNA-Dependent Protein Kinase to Restore Expression of IFN-Stimulated Genes in HCV-Infected Cells. Gastroenterology. 147(2). 463–472. 17 indexed citations

Watashi, Koichi, Ann E. Sluder, Takuji Daito, et al.. (2013). Cyclosporin A and Its Analogs Inhibit Hepatitis B Virus Entry Into Cultured Hepatocytes Through Targeting a Membrane Transporter, Sodium Taurocholate Cotransporting Polypeptide (NTCP). Hepatology. 59(5). 1726–1737. 205 indexed citations

Lavocat, Fabien, Paul Dény, Christian Pichoud, et al.. (2013). Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. Journal of Hepatology. 59(4). 684–695. 19 indexed citations

Svarovskaia, Evguenia S., Maria Curtis, Yuan Zhu, et al.. (2012). Hepatitis B virus wild‐type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir‐based regimen. Journal of Viral Hepatitis. 20(2). 131–140. 20 indexed citations

10.

McColl, Damian J., Nicolas Margot, Shanshan Chen, et al.. (2011). Reduced Emergence of the M184V/I Resistance Mutation When Antiretroviral-Naïve Subjects Use Emtricitabine Versus Lamivudine in Regimens Composed of Two NRTIs Plus the NNRTI Efavirenz. HIV Clinical Trials. 12(2). 61–70. 20 indexed citations

11.

Berg, Thomas, Patrick Marcellin, Fabien Zoulim, et al.. (2010). Tenofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated Patients With Chronic-Hepatitis B Virus Infection. Gastroenterology. 139(4). 1207–1217.e3. 115 indexed citations

12.

Manns, M.P., Jenny Heathcote, Patrick Marcellin, et al.. (2010). 1017 EFFICACY OF TENOFOVIR DF TREATMENT IN PATIENTS WITH A SUBOPTIMAL RESPONSE TO ADEFOVIR DIPIVOXIL. Journal of Hepatology. 52. S393–S393. 2 indexed citations

13.

Feng, Joy Y., Florence Myrick, Derrick Goodman, et al.. (2009). The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology. 6(1). 44–44. 54 indexed citations

14.

Berg, Thomas, Bjarne Kuno Møller, G Gerken, et al.. (2008). Tenofovir disoproxil fumarate (TDF) versus Emtricitabine plus TDF for treatment of chronic Hepatitis B (CHB) in subjects with persistent viral replication receiving Adefovir dipivoxil (ADV). Zeitschrift für Gastroenterologie. 46(9). 6 indexed citations

15.

Borroto–Esoda, Katyna, et al.. (2007). Baseline Genotype as a Predictor of Virological Failure to Emtricitabine or Stavudine in Combination with Didanosine and Efavirenz. AIDS Research and Human Retroviruses. 23(8). 988–995. 27 indexed citations

16.

Curtis, Maria, Yuao Zhu, & Katyna Borroto–Esoda. (2007). Hepatitis B Virus Containing the I233V Mutation in the Polymerase Reverse‐Transcriptase Domain Remains Sensitive to Inhibition by Adefovir. The Journal of Infectious Diseases. 196(10). 1483–1486. 30 indexed citations

17.

Borroto–Esoda, Katyna, Michael D. Miller, & Sarah Arterburn. (2007). Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. Journal of Hepatology. 47(4). 492–498. 56 indexed citations

18.

Feng, Joy Y., Florence Myrick, Nicolas Margot, et al.. (2006). Virologic and Enzymatic Studies Revealing the Mechanism of K65R- and Q151M-Associated HIV-1 Drug Resistance Towards Emtricitabine and Lamivudine. Nucleosides Nucleotides & Nucleic Acids. 25(1). 89–107. 20 indexed citations

19.

Hadziyannis, Stephanos J., Nicolaos C. Tassopoulos, E. Jenny Heathcote, et al.. (2006). Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years. Gastroenterology. 131(6). 1743–1751. 703 indexed citations breakdown →

20.

Feng, Jiao, Florence Myrick, Boulbaba Selmi, et al.. (2005). Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (−)-β-d-1′,3′-dioxolan guanine. Antiviral Research. 66(2-3). 153–158. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact